Photo: Pradeep Gaur/MintNew Delhi: The rampant sale of unapproved antibiotics in India continues, triggering antimicrobial resistance in the country. The study also found that multinational companies manufactured nearly 20% of the FDCs and SDFs sold. In contrast, 94% of multinational companies’ single drug formulations were CDSCO-approved, and over 70% had UK or US regulatory approval. The researchers argue that changes needed to achieve the World Health Organization’s (WHO) vision of good use of antibiotics include banning the sale of unapproved FDC antibiotics and enforcing existing regulations to prevent unapproved and illegal drugs reaching the market. Improved access to healthcare to reduce non-prescription sales is also needed, along with research to understand why doctors prescribe unapproved antibiotics.

Source: Mint February 06, 2018 08:48 UTC